Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.

Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.

Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.